Fulvestrant

Catalog No.S1191 Synonyms: ICI-182780, ZD 9238

Fulvestrant Chemical Structure

Molecular Weight(MW): 606.77

Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • PTPH1 confers breast cancer cell sensitivity to fulvestrant. E and F, PTPH1 overexpression increases the growth inhibition by fulvestrant. PTPH1 was overexpressed by a Tet-on system or a stable transfection, and resultant cells were incubated with fulvestrant as indicated for about 2 weeks. Colony formed was stained and counted. Results shown are normalized to its own solvent control of Vector and PTPH1-overexpressed cells, respectively (means ± SD; n = 3–5) with insets showing PTPH1 overexpression. *, versus vector or no Tet cells for E and F.

    Mol Cancer Ther 2014 13(1), 230-8. Fulvestrant purchased from Selleck.

     

    Fulvestrant resistance induced by 6 different ZF-TFs. (A) Drug sensitivity of fulvestrant-selected MCF7 ZF-TF-transduced cells. MCF7 cells transduced with one of six different ZF-TF-expressing retroviruses selected first in puromycin (the transduction selection marker) and then in fulvestrant for 1 month were grown in the absence of fulvestrant for 7 days and then challenged with 100 nM fulvestrant or vehicle (0.1% ethanol) for 21 days followed by crystal violet staining and visualization. Data are representative of triplicate experiments.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

  • Fulvestrant resistance induced by 6 different ZF-TFs. (B and C) Growth curves of MCF7 and T47D cells in the presence and absence of fulvestrant. Comparison of cell growth rates (cell number, mean +/2 SEM, n = 8; time in days as indicated) of MCF7 and T47D cells stably transduced with control retrovirus or one of six different ZF-TF-expressing retroviruses (7, 19, 64, 70, 83 and 115) in the presence (blue line) or absence (pink line) of fulvestrant.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

    CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments. (c) MCF-7 and MR cells were treated with different concentrations of ICI, collected after 24 h and then immunoblotted with the indicated antibodies.

    Oncogene, 2017, 36(16):2255-2264. Fulvestrant purchased from Selleck.

  • A: Time dependent loss of MGMT activity in ERα-positive MCF7 and T47D tumor cells but not in ERα-negative MDAMB-468 cells after 1 μmol/L Fulvestrant treatment (upper panel). Concentration dependent inhibition of MGMT activity in MCF7 and T47D cells but not in MDA-MB-468 cells after a 72 hours exposure to fulvestrant (lower panel). The data represents the mean of two independent experiments in duplicate and the last time point (72 hours) as assessed by student's t-test was significant at P < 0.05. B: Decreased MGMT and ER-α protein levels in MCF7 cells after 48 hours and 72 hours fulvestrant exposure. ICI is fulvestrant, also called ICI-182,780. C: Decreased MGMT and ER-α protein levels in T47D cells after 48 hours and 72 hours fulvestrant exposure.

    J Biomed Res, 2016, 30(5):393-410. Fulvestrant purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.
Targets
ER [1]
(Cell-free assay)
0.94 nM
In vitro

Fulvestrant is an effective inhibitor of the growth of ER-positive MCF-7 (with IC50 of 0.29 nM) but with no effect on the growth of ER-negative BT-20 human breast cancer cells. Fulvestrant causes accumulation of cells in G0/G1 and also reduces the proportion of cells capable of continued DNA synthesis. [1] Fulvestrant competitively inhibits binding of oestradiol to the estrogen receptor. Fulvestrant blocks nuclear localization of the ER through impairing receptor dimerisation, and energy-dependent nucleo-cytoplasmic shuttling. Because of the instability of fulvestrant-ER complex, the binding of Fulvestrant with ER finally results in accelerated degradation of the ER protein. [2] Fulvestrant (10 nM) not only decreases IGF-IR mRNA levels but also decreases the half-life. [3] Treatment with 100 μM Fulvestrant leads to a time dependent increase of TNFR1 and TRADD steady-state mRNA levels in MCF-7 cells. [4] Fulvestrant is capable of down-regulating androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Fulvestrant also significantly attenuates R1881-stimulated growth by 70%. [5] Fulvestrant is able to modulate mitosis and cell death in immature cerebellar neurons via rapid activation of MAPK. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 M1LpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzZSWgyNjNvMUCwNEBvVQ>? MlLSOFghcA>? NHXxOWZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3S0bFI1QTd7Mkm0
MCF-7/LTED M13sS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7ITZYyNjNvMUCwNEBvVQ>? NWrPXHh3PDhiaB?= MkL2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHXBWoszPDl5OUK5OC=>
HCC1428 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKxMlMuOTByMDDuUS=> M{nwU|Q5KGh? M1rjOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnLnNlQ6Pzl{OUS=
HCC1428/LTED M3rxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX0Zm0yNjNvMUCwNEBvVQ>? MkniOFghcA>? MoPvbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXfPdlNzOjR7N{myPVQ>
LCC1 Mn:2SpVv[3Srb36gRZN{[Xl? NGTWVFcyODBibl2= NH\SNIo1QC1zNESgbC=> NHXneYdi[3SrdnH0[ZMhXVCUIIPp[45idGmwZx?= M2KyeVI1QDV6Mke3
LCC9 MYnGeY5kfGmxbjDBd5NigQ>? NHrqWmgyODBibl2= NF7WXnU1QC1zNESgbC=> M3y1ZYFkfGm4YYTld{BWWFJic3nncoFtcW6p NYXORYQ{OjR6NUiyO|c>
MCF-7  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:xNFAhdk1? NULKN3VOPSCm MoHMbY5pcWKrdIOgZ4VtdCCpcn;3eIghfG9iMUFvwKU> MWqyOFgyQTV3MB?=
mesangial  MlXsSpVv[3Srb36gRZN{[Xl? NYjifoxlOC5zLUGwNEBvVQ>? M2jhNFQ5KGh? MlThd5VxeHKnc4Pld{BVT0ZvzsKxMYlv\HWlZXSgeJlx\SCLVjDjc4xt[Wenbh?= NUPrU4s5OjR5OUO2N|k>
Mesangial Mly0SpVv[3Srb36gRZN{[Xl? NFjoe|UxNjFvMUCwJI5O M3e1blAvPSCq NF;nc4xqdmirYnn0d{BVT0ZvzsKxMYlv\HWlZXSgV41i\DJicHjvd5Bpd3K7bHH0bY9vKH[rYTDHVGVT MlHENlQ4QTN4M{m=
ER+ MCF-7/2a NE\FPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIniTopKSzVyPUCuNFA1KM7:TR?= NFvue24yPTN{NEi4OC=>
ER+ MCF-7 NV3JPWZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[wWZozODBiaB?= NVzEN2FYUUN3ME2wMlIyKG6P M{KxPFE2OzJ2OEi0
MCF-7  NUOzTlZ7TnWwY4Tpc44hSXO|YYm= MV:xNOKhdk4EoB?= MlroO|IhcA>? M2q0UpJmfmW{c3XzJJRp\SCnc4Tyc4dmdiCnZn\lZ5QpUUN3MDCxMlkhy5diMUFijLI6KE1r MWmyOFkxQDZ3Mh?=
MCF-7  M2ixPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW4RW9KSzVywrDv[kBieHC{b4jpcYF1\Wy7IEKgcm0> M4rufVI{PDR6M{S2
H1975  NWXhWYp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWezxsDPxE1? M1WwZlEhdQ>? NXziOlBrcW6lcnXhd4V{KHSqZTDn[YZqfGmwaXKgd4Vve2m2aY\peJkhd2ZiSEG5O|Uh[2WubIRCpC=> M4XoSFI1OjZ6OEGw
H1975 MXTGeY5kfGmxbjDBd5NigQ>? MoPQN:Kh|ryP M3W1cFEhdQ>? NGfxe2N2eHKnZ4XsZZRmeyC2aHWgcIV3\Wxib3[gUIV1NTel NH7CU4UzPDJ4OEixNC=>
MCF-7  NXzUTJgzTnWwY4Tpc44hSXO|YYm= MX:xNFDjiImwTdMg NHvFV2Y4OiCq MULy[ZZmenOnczD0bIUheHKxdHXjeIl3\SCnZn\lZ5Qhd2ZiRUNCpIlvKGOnbHygbY53[XOrb36= NYXYbG1JOjN7M{[3O|M>
MCF-7  M3PNb2Z2dmO2aX;uJGF{e2G7 NYDs[5hEOTBy4pEJcm3DqA>? NFL0NIszPC92ODDo NUPob5pP\mGlaXzpeIF1\XNiaX72ZZNqd25idHjyc5VocCCPTWDzK{Bud2S3bHH0bY9v MlLHNlM6OzZ5N{O=
BT474-tet-shMED1 MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXiwMlEuPSEQvF2= NF3URYM4KGR? MlPPbY5kemWjc3XzJEtFd3hiaX7keYNm\CClZXzsJIRm[XSqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{DEW|I{QTN4MkO0
ZR75-1-tet-shMED1  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr2ZnpEOC5zLUWg{txO NVjVXnFNPyCm NUG0bpVHcW6lcnXhd4V{KCuGb4igbY5lfWOnZDDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1TQVFI{QTN4MkO0
MCF-7-tet-shMED1 Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjkdZZVOC5zLUWg{txO MWC3JIQ> M2HIcolv[3KnYYPld{AsTG:6IHnu[JVk\WRiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NY\aOmY6OjN7M{[yN|Q>
HepG2  MWPGeY5kfGmxbjDBd5NigQ>? MV2wMlAyNTFyIN88US=> NUS5UVJUOThiaNMg MmC5ZYN1cX[jdHXzJJRp\SCHUlWtcYVlcWG2ZXSgeJJidnOlcnnweIlwdiCxZjDBSlJGWg>? MXyyN|c{OzF6OB?=
MCF-7L  MYTGeY5kfGmxbjDBd5NigQ>? MYWxNFAhdk4EoB?= MYixNEBucW5xMkSgbE81QCCq NFHlZnpz\XO3bITzJIlvKEWJRmKsJGhGWjJiYX7kJGhGWjNicHjvd5Bpd3K7bHH0bY9vKGG2IIDyc4xwdmenZDDlfJBwe3W{ZR?= MVGyN|Y5PjRzNh?=
MCF-7L  MmXzSpVv[3Srb36gRZN{[Xl? M1TtTFExOCCwTdMg NHHtXng1QCCq M4WzcIlv\HWlZYOgeZBz\We3bHH0bY9vKG:oIH3SUmEhd2ZiRVfGVkBtcWejbnSgTGIuTUeI MoTJNlM3QDZ2MU[=
MCF-7L NEnwTVFHfW6ldHnvckBCe3OjeR?= Mn2yNVAxKG6PwrC= MXq0PEBp MVTpcoR2[2W|IFXHSnIh\mGvaXz5JI1mdWKncjDhZ5RqfmG2aX;uJJJmeXWrcnXkJGVT MoLMNlM3QDZ2MU[=
C4-12  MmS3SpVv[3Srb36gRZN{[Xl? M2\zeFExOCCwTdMg MmHPOFghcA>? NX7ESnB4cW6mdXPld{BGT0[UIH\hcYltgSCvZX3i[ZIh[WO2aY\heIlwdiC{ZYH1bZJm\CCHUh?= NH3rPIgzOzZ6NkSxOi=>
MCF-7L NUnGdW1WTnWwY4Tpc44hSXO|YYm= NUjB[2ptOTByIH7NxsA> M13HO|I1KGh? NHLP[nJqdmS3Y3XzJGVITlJicHjvd5Bpd3K7bHH0bY9vKHKncYXpdoVlKEiELVXHSkBnfW6ldHnvci=> NGj4c3UzOzZ6NkSxOi=>
MMQ  M1TKTmZ2dmO2aX;uJGF{e2G7 NUnOZ4Z[OC14MkWgcm0> NH3rfZU4OiCq NIfySW9ld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDld5Rzd2enbjDy[YNmeHSxcj5OtUApTVMQsTm= MknUNlM2OjN|NUe=
H1975  NIPBZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTzNE4{OTJ3LUGwJO69VQ>? NWeyenpuPiCm MmfKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlH6NlM{QTl7NUe=
H1975  NEfi[YJCeG:ydH;zbZMhSXO|YYm= M3uyTFIxOCCwTR?= NV;1Z2I{PzJiaB?= MULlcohidmOnczDldoxwfGmwaXKgbY5lfWOnZDDhdI9xfG:|aYO= MV6yN|M6QTl3Nx?=
MCF-7  M4e4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zhSFExNzFyMD:xNFAxKG6P NUT0TYtZOi92L{[g[C=> NU\0e4x7TE2VTx?= MmG0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?= NV\hOpZiOjN|MUO1NFY>
MCF-7  MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rPfFExOCCwTR?= M{LkPFQh\A>? M{DjOWROW09? MnvSbY5lfWOnczDhJIhq\2incjDwdo9xd3K2aX;uJI9nKGOnbHzzJIlvKHSqZTDHNUBxcGG|ZdMg NXSxSnB2OjN|MUO1NFY>
MLO-Y4  NH22SpNHfW6ldHnvckBCe3OjeR?= M2DzelHDqM7:TR?= Mn7INUBp NXrUUFN{cW6qaXLpeJMhTTJvaX7keYNm\CCFeESzJIV5eHKnc4Ppc44> Mn23NlMzPDdyNUe=
MCF-7 NHjCeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LTWlExOCCwTR?= MWi0PEBp NXm3WGpn[WK{b3fheIV{KHSqZTDwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCvb3TldoF1\SCwaYTyc5NifGm4ZTDzeJJme3N? NVKwUmdpOjN{MU[3OFQ>
TG1-1  M3ToTWZ2dmO2aX;uJGF{e2G7 MYOxxsDPxE1? NWTmc5llOjRiaB?= M1TnfoFjem:pYYTld{BGOsLiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhUEmILUJOtS=> MWCyN|A5QDZyNx?=
TG1-1  M1y5UmZ2dmO2aX;uJGF{e2G7 M4fER|HDqM7:TR?= NYjPSnBMOjRiaB?= NX71OGdW[WK{b3fheIV{KEV{wrDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCSSUPL NXXxXnFOOjNyOEi2NFc>
MCF7 NX2zZXY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PqRlExOCCwTR?= M1;HZlQ5KGh? M2nxXYxm[WS|IITvJIEhe2mvaXzhdkBtd3O|IHnuJJN2en[rdnHsJIF{KHerdHig[I95d3K3YnnjbY4h[WyxbnW= MV[yN|A4PzJ2OR?=
MCF7 MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3CNVAxKG6P MXK0PEBp M{e3dYVvcGGwY3XzJI52fGyrbj3t[YRq[XSnZDDj[YxtKGSnYYTo NVXtV3FQOjNyN{eyOFk>
MCF-7  MUXGeY5kfGmxbjDBd5NigQ>? NX;uNHg2PiCq NXf2cVJ[TE2VTx?= NFTvVY9ifHSnboXheIV{KHSqZTDmcJVlcW:6b37pcE0hd3JiZnXubIV5[W2rZD3pcoR2[2WmIHnuZ5Jm[XOnIHnuJI1qWi1{MTDlfJBz\XO|aX;u NGXLRoszOzB3MkCzOi=>
MCF-7 NHHTPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3myO|ExOCCwTT:xJO69VQ>? NFP0OGY2KGR? M{OwfolvcGmkaYTzJJRp\SC|dHnteYxifGmxbjDv[kAyP87{LXXzeJJi\GmxbB?= NVjKfHB[OjJ7OEK3OlU>
MCF-7 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:1XnNmOTByIH7N MmrMOUBl NGrPV4RqdmirYnn0d{B1cGVic4TpcZVt[XSrb36gc4Yh\nW|YYLp[YxqdiCK MlTtNlI6QDJ5NkW=
1471.1 MYDGeY5kfGmxbjDBd5NigQ>? M4H2b|ExOCCwTR?= NYG4WXprOSCq MoO5SZRQUMLi NUjBRoRifGGtZYOgc44h[SCydX7jeIF1\SC|dHHpcolv\yCyYYT0[ZJv NXPqc|FrOjJ6NkmxNFY>
MCF-7 MmrUSpVv[3Srb36gRZN{[Xl? NE[zeYsyODBibl2= NWTrSZl4OSCq MkSxSZRQUMLi MkizeIFs\XNib36gZUBxfW6ldHH0[UB{fGGrbnnu[{Bx[XS2ZYLu M4TnN|IzQDZ7MUC2
HeLa Mm\zSpVv[3Srb36gRZN{[Xl? NUjLNVB3OTByIH7N MkH0NUBp NVfIblZuTXSRSNMg NGHW[Yl1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> MoPhNlI5PjlzME[=
COS-7  NHXteWdHfW6ldHnvckBCe3OjeR?= NELjZ4YyODBibl2= NIr5enQyKGh? M1fVe2V1V0kEoB?= NIjwR|F1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> NF7XSIMzOjh4OUGwOi=>
BG1L-OHTLT  NGnkPXdHfW6ldHnvckBCe3OjeR?= MoP1NVDDqG6P MmjONlTDqGkEoB?= NVrMZ2NrcW6qaXLpeJMhTVMQsTDlfJBz\XO|aX;u NIX4[G4zOjZ3MkW1PC=>
BG1L-ICILT M2e5XGZ2dmO2aX;uJGF{e2G7 NVfVU3llOTEEoH7N NHf6b2EzPMLiaNMg M2TEXIlvcGmkaYTzJGVT|rFiZYjwdoV{e2mxbh?= MVeyNlY2OjV3OB?=
PC-9 Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjyfYUxNjByMz2zNEDPxE1? NFzhNmM1QCCq M4K2eIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmXoNlI2PjB4M{S=
H1650 NXzwSmhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;0dVAvODB|LUOwJO69VQ>? MXe0PEBp NFfYeG1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Moq3NlI2PjB4M{S=
H1975 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTjR5QxNjByMz2zNEDPxE1? MkHQOFghcA>? Mmm0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2fyXFIzPTZyNkO0
H1975 NELEVpBHfW6ldHnvckBCe3OjeR?= NELhdmE{yqEQvF2= MVqzJIg> NH34cGFi[nKxZ3H0[ZMhfGinIIDoc5NxcG9vRVfGVkBqdmS3Y4Tpc44h[nliZYP0do9o\W5? NV7WO2M4OjJ3NkC2N|Q>
H1975 MWHGeY5kfGmxbjDBd5NigQ>? NGC5Xpo{yqEQvF2= M{\Fflch\A>? MWLpcoR2[2W|IFXHSnIh\XiycnXzd4lwdg>? NX61SJRJOjJ3NkC2N|Q>
HTR-8 MmP3SpVv[3Srb36gRZN{[Xl? MYGxxsDPxE1? NGrmXIIyNTR6IHi= MnrS[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSVfGRnA4KG2UTlG= NUTtfpJkOjJ|OEOxNVE>
JEG-3 NGnQc21HfW6ldHnvckBCe3OjeR?= M4n6VVHDqM7:TR?= NYDERWtYOS12ODDo NYDwfJgz\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[gTWdHSlB5IH3SUmE> NV;JdVFIOjJ|OEOxNVE>
Huh7 NVXPO2g5TnWwY4Tpc44hSXO|YYm= Mlz0OVDDqM7:TR?= NYC1WI5SPDhiaB?= MWLpcohq[mm2czDn[Y5qe3SnaX6tcYVlcWG2ZXSgVG9POSC2cnHud4FkfGm4YYTpc44> NHvCVIQzOjNyNEK5Oi=>
201T M1zEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zLeVUh|ryP NXXOeIhzPzJiaB?= NUHqTFc{cW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqII\hcoRmfGGwaXK= M3nFVFIzOjV6NEe2
A549  M4nTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjU[3VjPSEQvF2= NUWxOJJOPzJiaB?= NV3WVVhDcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqII\hcoRmfGGwaXK= NIfTTJczOjJ3OES3Oi=>
MCF-7 MUfGeY5kfGmxbjDBd5NigQ>? NFrGOncyyqEQvF2= NFLMOZczPCCqwrC= NGTIXlNld3ewcnXneYxifGW|IFXSJIV5eHKnc4Ppc44hcW6mdXPl[EBjgSB2LV;IMXQhyqB? NVPoe5poOjJyNEmzNVY>
HCC-1428 MlLtSpVv[3Srb36gRZN{[Xl? NX7NelkzOcLizszN NF\2fmYzPCCqwrC= NYnBcZZW\G:5boLl[5Vt[XSnczDFVkBmgHC{ZYPzbY9vKGmwZIXj[YQh[nliND3PTE1VKMLi NFruSokzOjB2OUOxOi=>
MDA-361 MkT3SpVv[3Srb36gRZN{[Xl? NV3x[oFFOcLizszN MUKyOEBpyqB? M32zXYRwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvckBqdmS3Y3XkJIJ6KDRvT1itWEDDqA>? M13tNlIzODR7M{G2
ZR75-1 NYq0[mdYTnWwY4Tpc44hSXO|YYm= Mn7MNeKh|ryP NEPZPVczPCCqwrC= M1PvWIRwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvckBqdmS3Y3XkJIJ6KDRvT1itWEDDqA>? MV2yNlA1QTNzNh?=
MCF-7 M2rjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\DNeKh|ryP NU\SNFBQPS1zMDDk NWr1[I5Xe3WycILld5NmeyCHMj3pcoR2[2WmIHfyc5d1cCCrbnjpZol1cW:w NYrWbVl1OjJyNEmzNVY>
HCC-1428 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHQRYk4OcLizszN MlvDOU0yOCCm NGTVOYl{fXCycnXzd4V{KEV{LXnu[JVk\WRiZ4Lve5RpKGmwaHnibZRqd25? MoDENlIxPDl|MU[=
MDA-361 NGHCNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXYSoNsOcLizszN NGnudGY2NTFyIHS= MnvZd5VxeHKnc4Pld{BGOi2rbnT1Z4VlKGe{b4f0bEBqdmirYnn0bY9v NWT4OGpwOjJyNEmzNVY>
ZR75-1 NEj3V3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2wemhROcLizszN MkHqOU0yOCCm MYrzeZBxemW|c3XzJGUzNWmwZIXj[YQh\3Kxd4ToJIlvcGmkaYTpc44> Mn\pNlIxPDl|MU[=
MCF-7/AC-1 NIjaNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr6OlQ6OC1yLkKg{txO Moq2OkBl MUjpcohq[mm2czDj[YxtKGe{b4f0bEBud2Snc4TsfS=> NETZZZUzOjB2Mke5Ni=>
MCF7 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[xNEDDvU1? MYe0PEBp NVf2fVA1cW6mdXPld{Bk\WyuIHnubIljcXSrb36ge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IH\pZpJw[myjc4Tz NGOzRW0zOjB2MUi4Oy=>
MMQ NUX0RmZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m3NFAuPjJ3IH7N MYW3NkBp NV7YUJR4eHKxZIXj[ZMhe3SjdHnzeIlk[WyueTDzbYdvcW[rY3HueEBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbtMg M4DKZlIzODF3MUCx
MMQ MlflSpVv[3Srb36gRZN{[Xl? Mm\FNE03OjVibl2= NHLU[IU4OiCq NIL5fndxem:mdXPld{BiKHO2YYTpd5Rq[2GubImgd4lodmmoaXPhcpQtKGSxc3Wt[IVx\W6mZX70JJJm\HWldHnvckBqdiCSUlygd4VkemW2aX;u M1S4bVIzODF3MUCx
MCF7 NGH6Tm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjRNE0yKM7:TR?= NV\2cok4OjRvMUKwJIg> Mlf3bY5pcWKrdIOgeIhmKGe{b4f0bEBw\iCPQ1[3MXlDNTIEoB?= MUOyNVg3OzJ3OB?=
HepG2 MVzBdI9xfG:|aYOgRZN{[Xl? Ml[yNE4yyqEQvF2= MVyyOEBp NUjJcmpJ[WKxbHnzbIV{KHSqZTDld5Rzd2enbj3pcoR2[2WmIIXwMZJm\3WuYYTpc44hd2ZiYYDvRWkh[W6mIHHwc20> MoD3NlE5OTZ{M{O=
MCF7–iFR3 M3i2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;Mfm1jOjBvMUCwJI5O MmjGPVYhcA>? NGHQbYRmdmijbnPld{BCWC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= NIHHSpQzOTd7Mki4PS=>
MCF7S NFz2cIFHfW6ldHnvckBCe3OjeR?= NH;hSZEyyqEQvF2= NFnhcpg1QCCq MlXr[I94dnKnZ4XsZZRmeyCxdnXyZYxtKEWUzsGgdJJwfGWrbjDs[ZZmdHN? NEfiXnMzOTV|M{G5OS=>
MCF7 MVPGeY5kfGmxbjDBd5NigQ>? MkTBNeKh|ryP MnPEOFghcA>? NYmyXHdW\G:5boLl[5Vt[XSnczDveoVz[WyuIFXS{tEheHKxdHXpckBt\X[nbIO= M3n3[VIyPTN|MUm1
MCF7S MXPGeY5kfGmxbjDBd5NigQ>? NGfYe4UyyqEQvF2= NXLqPW1lPyCm NH\p[I9ifHSnboXheIV{KHS3bX;yd5Bp\XKnIH\vdo1ifGmxbjDhcoQheHKxbHnm[ZJifGmxbh?= MYKyNVU{OzF7NR?=
MCF7S MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELTNmExNjVxMTFOwG0> Mlq5O{Bl MYTEUXNQ NVLZWJZ4\GWlcnXhd4V{KGOnbHyg[Zhx[W6|aX;u MnnFNlE2OzNzOUW=
T47D  NW\uT4hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG2U4M1KG6P MYS0NEBp MmHld5VxeHKnc4Pld{Bk\WyuIHfyc5d1cCCvb3TldoF1\Wy7 M{XwVlIyPDhyM{mx
BT474  NGnMRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPPZnY1KG6P M3HjUlQxKGh? NHjIWXJ{fXCycnXzd4V{KGOnbHyg[5Jwf3SqIH3v[IVz[XSnbIm= MWOyNVQ5ODN7MR?=
T47D  NXS5VHk{TnWwY4Tpc44hSXO|YYm= NWnlVooyOTBibl2= NHvIRpM1OCCq MoDx[I94dnKnZ4XsZZRmeyCHUt8xJJBzd3SnaX6= MUiyNVQ5ODN7MR?=
BT474  M3vyPWZ2dmO2aX;uJGF{e2G7 MlTaNVAhdk1? NUL5Xmx[PDBiaB?= M4PHZ4Rwf26{ZXf1cIF1\XNiRWNOtUBxem:2ZXnu NYXHT21jOjF2OECzPVE>
MCF7 MUPGeY5kfGmxbjDBd5NigQ>? Ml3XNVAxKG6P NWrWSll2PyCm M1j5SpJm\HWlZYOgSXLPuSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk> MYmyNVM6PjB7NB?=
T47D  NVvB[Ic3TnWwY4Tpc44hSXO|YYm= MUKxNFAhdk1? NWDGboYzPyCm NGf2c4Vz\WS3Y3XzJGVT|rFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 NHjUc2czOTN7NkC5OC=>
BT474  NYTTV4ZuTnWwY4Tpc44hSXO|YYm= NG\KOHYyODBibl2= Mm\tO{Bl MU\y[YR2[2W|IFXS{tEh\XiycnXzd4lwdiC|aXfubYZq[2GwdHz5 NV\SRXBJOjF|OU[wPVQ>
MDAMB361 NYHxVJViTnWwY4Tpc44hSXO|YYm= NF7ofmcyODBibl2= MVq3JIQ> NIDL[IFz\WS3Y3XzJGVT|rFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 NVnUXFNsOjF|OU[wPVQ>
MCF7 NFTN[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGwMlAyNTFizszN NG\zRmk4KGR? NWLj[W9wemWmdXPld{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 Ml3CNlE{QTZyOUS=
T47D  NGHhXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[wMlAyNTFizszN MVe3JIQ> MkPHdoVlfWOnczDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 M2rLUFIyOzl4MEm0
BT474  M3POcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\DV5VKOC5yMT2xJO69VQ>? NWLEO3RkPyCm NGnXbWpz\WS3Y3XzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= Mle3NlE{QTZyOUS=
MDAMB361 M2fRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W2b|AvODFvMTFOwG0> MkLEO{Bl MWXy[YR2[2W|IHPlcIwh\3Kxd4ToJJNq\26rZnnjZY51dHl? NIHkXZAzOTN7NkC5OC=>
MCF7 NGW2XINHfW6ldHnvckBCe3OjeR?= NUTCOmxZOTByIH7N NED4bFE4KGR? NXfSdnFzcW6mdXPld{Bw\iCHcnLCN{BidmRiRYLiRlQhemWlZYD0c5Ih\XiycnXzd4lwdiCjbnSgd4lodmGubHnu[y=> NX61b|lxOjF|OU[wPVQ>
T47D  NUfqU3RPTnWwY4Tpc44hSXO|YYm= NGnQS|UyODBibl2= M1XqcFch\A>? MmXkbY5lfWOnczDv[kBGemKEMzDhcoQhTXKkQkSgdoVk\XC2b4Kg[ZhxemW|c3nvckBidmRic3nncoFtdGmwZx?= MXWyNVM6PjB7NB?=
BT474  Ml;QSpVv[3Srb36gRZN{[Xl? NGfHUI0yODBibl2= M2[3PVch\A>? NXyzT|A4cW6mdXPld{Bw\iCHcnLCN{BidmRiRYLiRlQhemWlZYD0c5Ih\XiycnXzd4lwdiCjbnSgd4lodmGubHnu[y=> Mlj2NlE{QTZyOUS=
MDAMB361 MX3GeY5kfGmxbjDBd5NigQ>? NGTOVGQyODBibl2= M2P3c|ch\A>? NUDoNohtcW6mdXPld{Bw\iCHcnLCN{BidmRiRYLiRlQhemWlZYD0c5Ih\XiycnXzd4lwdiCjbnSgd4lodmGubHnu[y=> NWnCWYw3OjF|OU[wPVQ>
MCF7 MWLGeY5kfGmxbjDBd5NigQ>? NEmyTHQyOCCwTR?= NW\tTGh2QTZiaB?= MmO1[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uxsA> NH\hSm8zOTN5OEOzNy=>
MDA-MB-231 M4jGOWZ2dmO2aX;uJGF{e2G7 NYjZZmR[OTBibl2= MXK5OkBp MXzkc5dvemWpdXzheIV{KEWUIHX4dJJme3Orb39CpC=> M2TUTlIyOzd6M{Oz
SK-BR-3 MkfuSpVv[3Srb36gRZN{[Xl? MlfrNVAhdk1? M3;ST|k3KGh? M1XRW4Rwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvcuKh M4H1NlIyOzd6M{Oz
MCF-7 NHPicndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLPNVAxKG6P NUPJSmZRPzJxOU[gbC=> NX\MSnNu[2G3c3XzJINmdGxiY4njcIUh[XK{ZYP0 M3;Gb|IyOjl7OE[y
MMQ MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;MVIoxNjByOD22NlUhdk1? NFq5Upk4OiCq MX3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUTKPZpNOjB5MEC3OVU>
MMQ M4nDbGZ2dmO2aX;uJGF{e2G7 NGjrPWIxNjByOD22NlUhdk1? NHKwN5o4OiCq NHfK[ppqdmirYnn0d{BRWkxic3XjdoV1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{f4XFIxPzByN{W1
MMQ M{PudGZ2dmO2aX;uJGF{e2G7 NY[3[Gt{OC5yND22NlUhdk1? NVnEeYtNPzJiaB?= NYnqVolmcW6qaXLpeJMhTVMQsTDlfJBz\XO|aX;u NFPjeWgzODdyMEe1OS=>
MMQ MoTaSpVv[3Srb36gRZN{[Xl? NXTyPGI2OC5yND22NlUhdk1? NITaepk4OiCq M2fadJVxemWpdXzheIV{KFSJRt8yN{BidmRiVFfG{tJTUUliZYjwdoV{e2mxbh?= NWjmUYZ{OjB5MEC3OVU>

... Click to View More Cell Line Experimental Data

In vivo Fulvestrant is devoid of uterotropic activity, and when co-administered with estradiol, it effectively blocks the uterotropic action of estradiol with ED50 of 0.06 mg/kg/day s.c. in immature female rats. A single s.c. injection of 5 mg of Fulvestrant suspension blocks completely the growth of MCF-7 xenografts. The growth of transplants of the BrlO human breast tumor is also suppressed effectively by 10 μM Fulvestrant. [1] Fulvestrant (10 mg/rat, s.c.) reduces the androgen receptor expression, ERK1/2 phosphorylation and cell proliferation in the rat ventral prostate. [7] Fulvestrant also displays anti-angiogenesis in the chick egg chorioallantoic membrane. [8]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MCF-7 breast cancer cells
  • Concentrations: 2.9 nM
  • Incubation Time: 5 days
  • Method: MCF-7 cells are cultured in multiwell plates (24-well, seeding density 4 × 104) in minimal essential medium containing phenol red, insulin (10 μg/mL), and 5% charcoal-stripped fetal calf serum without additional estradiol. Fulvestrant and/or estradiol are added in fresh medium 2 days after seeding. Cultures are maintained for 5 days with one further medium change and growth is assessed by measurement of total cell protein at the beginning and end of treatment and compared with that of controls treated with ethanol (0.1%) alone.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: The human breast cancer xenografts MCF-7 in nude mice
  • Formulation: 50 mg/mL in arachis oil
  • Dosages: 5 mg/mouse
  • Administration: s.c. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (164.8 mM)
Ethanol 100 mg/mL warmed (164.8 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+95% Corn oil
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 606.77
Formula

C32H47F5O3S

CAS No. 129453-61-8
Storage powder
in solvent
Synonyms ICI-182780, ZD 9238

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01797120 Active, not recruiting Metastatic Breast Cancer PrECOG, LLC.|Novartis May 31, 2013 Phase 2
NCT01633060 Active, not recruiting Metastatic Breast Cancer Novartis Pharmaceuticals|Novartis October 3, 2012 Phase 3
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT03024580 Not yet recruiting Breast Neoplasm Instituto Nacional de Cancer, Brazil|Cancer Research UK Cambridge Institute March 2017 Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3
NCT02983604 Recruiting Advanced Estrogen Receptor Positive HER2- Breast Cancer Gilead Sciences January 2017 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is there any information for the half-life of fulvestrant (Cat No.S1191)?

  • Answer:

    S1191, is about 13.5 to 18.5 hours in vivo: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750771/. The half life of these compounds in cell culture might be different and we generally recommend replenishing with fresh drug every 24-48 hours.

Estrogen/progestogen Receptor Signaling Pathway Map

Estrogen/progestogen Receptor Inhibitors with Unique Features

Related Estrogen/progestogen Receptor Products

Tags: buy Fulvestrant | Fulvestrant ic50 | Fulvestrant price | Fulvestrant cost | Fulvestrant solubility dmso | Fulvestrant purchase | Fulvestrant manufacturer | Fulvestrant research buy | Fulvestrant order | Fulvestrant mouse | Fulvestrant chemical structure | Fulvestrant mw | Fulvestrant molecular weight | Fulvestrant datasheet | Fulvestrant supplier | Fulvestrant in vitro | Fulvestrant cell line | Fulvestrant concentration | Fulvestrant nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID